GELNIQUE 3% Drug Patent Profile
✉ Email this page to a colleague
When do Gelnique 3% patents expire, and when can generic versions of Gelnique 3% launch?
Gelnique 3% is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in GELNIQUE 3% is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.
Summary for GELNIQUE 3%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 5 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GELNIQUE 3% |
DailyMed Link: | GELNIQUE 3% at DailyMed |
Recent Clinical Trials for GELNIQUE 3%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 3 |
Academic and Community Cancer Research United | Phase 3 |
University of Colorado, Denver | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for GELNIQUE 3%
US Patents and Regulatory Information for GELNIQUE 3%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GELNIQUE 3%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for GELNIQUE 3%
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Teva B.V. | Kentera (previously Oxybutynin Nicobrand) | oxybutynin | EMEA/H/C/000532 Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. |
Authorised | no | no | no | 2004-06-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for GELNIQUE 3%
See the table below for patents covering GELNIQUE 3% around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2008012071 | ⤷ Try a Trial | |
Japan | 2015131826 | 経皮オキシブチニン療法のための組成物および方法 (COMPOSITIONS AND METHODS FOR TRANSDERMAL OXYBUTYNIN THERAPY) | ⤷ Try a Trial |
European Patent Office | 1670433 | FORMULATION PHARMACEUTIQUE TRANSDERMIQUE VISANT A REDUIRE LES RESIDUS SUR LA PEAU (TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES) | ⤷ Try a Trial |
Japan | 2011236250 | USE AND FORMULATION FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENT | ⤷ Try a Trial |
Germany | 60127134 | ⤷ Try a Trial | |
European Patent Office | 1280486 | REDUCTION D'EPISODES INDESIRABLES ASSOCIES A UNE THERAPIE PAR L'OXYBUTYNINE (MINIMIZING ADVERSE EXPERIENCE ASSOCIATED WITH OXYBUTYNIN THERAPY) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |